MSB 5.11% $1.44 mesoblast limited

is MESO getting beat to the punch on...

  1. 151 Posts.
    lightbulb Created with Sketch. 29
    The U.S. Food and Drug Administration on Friday approved Incyte Corp's treatment for acute Graft versus Host disease (GvHD), an inflammatory response by the immune system after a bone marrow transplant. The drug, ruxolitinib, sold under the brand
    The U.S. Food and Drug Administration on Friday approved Incyte Corp's treatment for acute Graft versus Host disease (GvHD), an inflammatory response by the immune system after a bone marrow transplant. The drug, ruxolitinib, sold under the brand
    finance.yahoo.com
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.44
Change
0.070(5.11%)
Mkt cap ! $718.0M
Open High Low Value Volume
$1.40 $1.48 $1.40 $2.308M 1.597M

Buyers (Bids)

No. Vol. Price($)
4 36810 $1.44
 

Sellers (Offers)

Price($) Vol. No.
$1.45 94105 1
View Market Depth
Last update - 16.10pm 24/06/2019 (20 minute delay) ?
(live)
Last
$1.44
  Change
0.070 ( 6.67 %)
Open High Low Volume
$1.40 $1.48 $1.40 185313
Last updated 15.59pm 24/06/2019 (live) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.